Eiger BioPharma up as COVID therapy cuts hospitalization risk by 50% in study

Eiger Biopharmaceuticals

17/03/2022 15:23

** Shares of drug developer  EIGR.O  rise ~41.8% to $8.07
    ** Co says its experimental drug, Lambda, significantly
reduced risk of COVID-related hospitalizations or emergency room
visits by 50% and death by 60% in late-stage study  urn:newsml:reuters.com:*:nPn2r4TqCa
    ** Study conducted in outpatients with COVID-19, and final
analyses evaluated data from 1,936 patients, with 84% of
patients having received at least on dose of COVID-19 vaccine
    ** Lambda is administered as one-time, subcutaneous dose to
outpatients
    ** Eiger plans to discuss results with FDA and submit an EUA
as soon as possible
    ** Eiger is also developing Lambda as standalone therapy and
in combination with other drugs for treatment of hepatitis delta
virus (HDV) infection
    ** Stock up ~55.78% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))